GfK CEO snags lifetime achievement award

Share this article:

Richard Vanderveer, PhD, group CEO, GfK US Healthcare Companies, accepted a lifetime achievement award last month from the Pharmaceutical Business Intelligence and Research Group (PBIRG).

The award recognizes Vanderveer’s 35-year career in the pharmaceutical industry.
Over the next five years, pharmaceutical marketing researchers should help reinvent the pharmaceutical industry, which is in “rather dire straits,” Vanderveer said in his acceptance speech at PBIRG’s annual conference in Savannah, GA. “We now must turn our attention to helping the industry develop a more effective, efficient way of communicating with our key stakeholders.”


Vanderveer, whose column, “Vantage Point,” appears on MM&M’s new Marketing Research page, taught the industry to use Individual Physician Level Prescribing Data (IPLRx) in the early 1990s. His contributions also include pioneering several new marketing research methodologies, developing numerous training programs and founding several successful marketing research organizations.


Past recipients of the PBIRG award have included Alice Burstein of Pfizer, Alan Bowditch of Martin Hamblin and Cliff Kalb, formerly of Merck.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...